lifestyle.marketresearchjournals.com

Author: Jaguar Health, Inc.

Jaguar Health Reports Approval of All Proposals at April 2026 Special Meeting of Stockholders

April 20, 2026
Artificial Intelligence (AI) Platforms Could Enhance Jaguar Health’s Development and Anticipated Commercialization of Crofelemer for Rare Disease Intestinal Failure (IF) Programs

April 13, 2026
Reminder: Jaguar Health to Host Investor Webcast at 8:30 am Eastern on Friday, April 10, 2026 Regarding Q4 2025 Financials and Company Updates

April 9, 2026
Jaguar Health Completes Effectiveness Trial to Support FDA Approved Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs

April 8, 2026
Jaguar Health Reports 2025 Financials

April 7, 2026
Jaguar Health Family Company Napo Pharmaceuticals Co-Sponsoring Pediatric Gastroenterology Conference: Elite Ped-GI Congress

April 2, 2026
FDA Feedback Supports Extension Phase for Jaguar Health’s Clinical Trial of Crofelemer for Treatment of Microvillus Inclusion Disease (MVID)

March 18, 2026
Jaguar Health Presenting March 12 at the Life Sciences Virtual Investor Forum to Provide Updates on Near-Term Catalysts

March 11, 2026
Jaguar Health Strengthens Company’s Balance Sheet by Restructuring and Reducing Royalty and Debt Obligations and Extinguishing Warrants

March 9, 2026
Jaguar Health Secures an Additional $3 Million Payment from Future Pak for Mytesi and Canalevia-CA1

March 3, 2026